{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:30:41Z","timestamp":1760783441670,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ecl.2011.05.008","type":"journal-article","created":{"date-parts":[[2011,9,2]],"date-time":"2011-09-02T13:03:48Z","timestamp":1314968628000},"page":"549-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of Bone Disease in Patients Undergoing Hormonal Therapy for Breast Cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Faryal Sardar Ali","family":"Mirza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ecl.2011.05.008_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women","volume":"115","author":"Love","year":"1991","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.ecl.2011.05.008_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2011.05.008_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","article-title":"Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status","volume":"24","author":"Vehmanen","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2011.05.008_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ctrv.2007.04.005","article-title":"Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?","volume":"33","author":"Ding","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.ecl.2011.05.008_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2011.05.008_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF01806160","article-title":"Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen","volume":"39","author":"Kristensen","year":"1996","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ecl.2011.05.008_bib8","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"17","key":"10.1016\/j.ecl.2011.05.008_bib9","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","article-title":"Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women","volume":"43","author":"McCloskey","year":"2007","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","article-title":"Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women","volume":"17","author":"Heshmati","year":"2002","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2011.05.008_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/978-3-642-55647-0_9","article-title":"Aromatase inhibitors in prevention\u2013data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study)","volume":"163","author":"Cuzick","year":"2003","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"10.1016\/j.ecl.2011.05.008_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3747\/co.2007.117","article-title":"The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial","volume":"14","author":"Richardson","year":"2007","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2011.05.008_bib13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"issue":"3 Pt 2","key":"10.1016\/j.ecl.2011.05.008_bib14","doi-asserted-by":"crossref","first-page":"1037s","DOI":"10.1158\/1078-0432.CCR-05-2458","article-title":"Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data","volume":"12","author":"Buzdar","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ecl.2011.05.008_bib15","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.ecl.2011.05.008_bib16","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1200\/JCO.2007.10.8274","article-title":"Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy","volume":"25","author":"Jones","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2011.05.008_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3816\/CBC.2008.n.065","article-title":"The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer","volume":"8","author":"Jones","year":"2008","journal-title":"Clin Breast Cancer"},{"issue":"22","key":"10.1016\/j.ecl.2011.05.008_bib18","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer","volume":"23","author":"Lonning","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9484","key":"10.1016\/j.ecl.2011.05.008_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bone.2006.06.027","article-title":"Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane","volume":"40","author":"Gonnelli","year":"2007","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.ecl.2011.05.008_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A\u00a0randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2011.05.008_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ecl.2011.05.008_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A\u00a0randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ecl.2011.05.008_bib24","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-5122(96)01080-8","article-title":"Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis","volume":"26","author":"Zheng","year":"1997","journal-title":"Maturitas"},{"issue":"18","key":"10.1016\/j.ecl.2011.05.008_bib27","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1073\/pnas.1533207100","article-title":"Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator","volume":"100","author":"Cenci","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"923","key":"10.1016\/j.ecl.2011.05.008_bib28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/pmj.78.923.526","article-title":"Osteoporosis","volume":"78","author":"Tuck","year":"2002","journal-title":"Postgrad Med J"},{"issue":"4","key":"10.1016\/j.ecl.2011.05.008_bib29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bone.2006.04.035","article-title":"A\u00a0single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats","volume":"39","author":"Gasser","year":"2006","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.ecl.2011.05.008_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2011.05.008_bib31","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","article-title":"Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial","volume":"12","author":"Markopoulos","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.ecl.2011.05.008_bib32","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1447-0756.2007.00634.x","article-title":"Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients","volume":"33","author":"Yonehara","year":"2007","journal-title":"J\u00a0Obstet Gynaecol Res"},{"issue":"3","key":"10.1016\/j.ecl.2011.05.008_bib33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"issue":"19","key":"10.1016\/j.ecl.2011.05.008_bib34","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ecl.2011.05.008_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2011.05.008_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2011.05.008_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2011.05.008_bib38","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2011.05.008_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.breast.2009.12.001","article-title":"Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy","volume":"19","author":"Hines","year":"2010","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.ecl.2011.05.008_bib40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.ecl.2011.05.008_bib41","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ecl.2011.05.008_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2009.12.001","article-title":"Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis","volume":"117","author":"Valachis","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"21","key":"10.1016\/j.ecl.2011.05.008_bib44","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ecl.2011.05.008_bib45","first-page":"S1","article-title":"NCCN task force report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2011.05.008_bib46","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.ecl.2011.05.008_bib47","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2011.05.008_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852911000570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:49Z","timestamp":1760175349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852911000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0889852911000570"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2011.05.008","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Bone Disease in Patients Undergoing Hormonal Therapy for Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2011.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}